Rituximab (anti-CD20)

製品コードA2009 別名: IDEC-C2B8

製品コード：A2009 純度：99%

Rituximab is a chimeric anti-CD20 mAb that binds the CD20 antigen on B cells with a binding affinity of 5 nM, MW: 143.86 KD.

サイズ	価格(税別)	在庫状況
1mg	JPY 44500	国内在庫あり
1mg*5	JPY 146500	お問い合わせ
5mg	JPY 146500	国内在庫あり
1mg*25	JPY 445500	お問い合わせ

代表番号: 045-509-1970\|電子メール：[email protected] よく尋ねられる質問

文献中Selleckの製品使用例（11）

質量管理及び製品安全説明書

現在のバッチを見る：純度： 99% タンパク質濃度： 3. 83mg/ml 内毒素：＜1EU/mg

Immunology & Inflammation related阻害剤の選択性比較

生物活性

製品説明

Rituximab is a chimeric anti-CD20 mAb that binds the CD20 antigen on B cells with a binding affinity of 5 nM, MW: 143.86 KD.

同型

Human IgG1

Targets

CD20 ^[1]

In Vitro
In Vitro	Anti-CD20 IgG1 antibody (rituximab), induces strong antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) effects on CD20+ Raji cells with the EC50 at 0.0365 nM and 1.5 nM, respectively.^[1]
細胞実験	For ADCC experiments, PBMCs were isolated from healthy human donor blood to serve as effector cells and were plated with target Raji cells at E:T ratio of 50:1 in the presence of indicated concentrations of KPL-404, anti-CD20, or isotype antibodies. Target Raji cells were labeled with calcein-AM for detection of cell lysis prior to experimental set up. Following incubation for 4 hours at 37°C in 5% CO₂, supernatants from the experiment were analyzed. For CDC experiments, human complement was plated with calcein-AM labeled target Raji cells in the presence of indicated concentrations of KPL-404, anti-CD20, or isotype antibodies. Following incubation for 4 hours at 37°C in 5% CO₂, supernatants from the experiment were analyzed.

In Vivo
In Vivo	A number of in vivo tumor models suggest the anti-tumor activity of rituximab is dependent, at least in part, on complement^[2]. Rituximab can deplete B cells for several months and, as such, could represent an effective therapy for B cell-mediated autoimmune diseases. Rituximab is now widely used in onco-haematology and is currently in development in several autoimmune diseases^[3].
動物試験	Objective: To study the mechanisms of follicular lymphoma’s resistance to rituximab Animal Models: Female CB17 severe combined immunodeficient(SCID) mice were injected (s.c.) with rituximab-resistant lymphoma cells (derived from a human FL) Formulation: -- Dosages: 10mg/kg, weekly Administration: i.p. Reference: https://www.ncbi.nlm.nih.gov/pubmed/19188155 Objective: To investigate the therapeutic effect of rituximab in combination with L19-IL2 on B-cell malignancies Animal Models: CB17/lcr severe combined mmunodeficiency (SCID) mice were injected (s.c.) Ramos or DoHH-2 lymphoma cells Formulation: saline Dosages: 200 μg Administration: i.v. Reference: https://www.ncbi.nlm.nih.gov/pubmed/19005180 Rituximab can apply to immunodeficient mice (eg: SCID mice), lymphoma cell lines and other related assays (Only for Reference)

参考
[1] Muralidharan S, et al. J Pharmacol Exp Ther. 2022 Apr;381(1):12-21. [2] George J. Weiner, et al. Semin Hematol. 2010, 47(2): 115-123. [3] Cartron G, et al. Crit Rev Oncol Hematol. 2007, 62(1):43-52.

参考

製品説明

CAS No.	174722-31-7
Formulation	PBS buffer, pH 7.2
Isotype	Human IgG1
Source	CHO cells
Storage (From the date of receipt)	Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
Shipping	Shipped under low temperature conditions
Sterility	8.65mg/ml

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

よくある質問（FAQ）

質問：1：
How to store the antibody?

回答：
Store the undiluted solution at 4 °C in the dark. Freezing antibodies can result in a loss of activity caused by the freezing/thawing process. Diluting antibodies to working concentrations and storing at 4°C for more than a day should be avoided. Additionally, make sure to keep the antibody sterile. Under these storage conditions, your antibodies should remain active for up to one year and oftentimes longer.